Free tool
FAERS Monitor: Trodelvy
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761115 or its brand name (Trodelvy, Sacituzumab Govitecan-Hziy). Reports on generic versions are filed under their own applications.
Reports
4,834
Serious
4,329
90% of reports
Hospitalization
1,310
Death reported
1,014
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression1,368
- diarrhoea615
- neutropenia549
- death491
- nausea281
- fatigue273
- triple negative breast cancer229
- febrile neutropenia219
- asthenia217
- off label use207
- alopecia176
- inappropriate schedule of product administration170
- neutrophil count decreased148
- thrombocytopenia147
- vomiting145
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 2 |
| 2020 | 112 |
| 2021 | 397 |
| 2022 | 1,248 |
| 2023 | 579 |
| 2024 | 714 |
| 2025 | 967 |
| 2026 | 815 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,325 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| triple negative breast cancerSignal | 229 | 2245.9 | 1919.7 | 337,532 |
| disease progressionSignal | 1,368 | 50.9 | 48.6 | 66,447 |
| neutropeniaSignal | 549 | 17.6 | 16.3 | 8,619 |
| neutrophil count decreasedSignal | 148 | 15.9 | 13.5 | 2,041 |
| febrile neutropeniaSignal | 219 | 14.4 | 12.7 | 2,719 |
| thrombocytopeniaSignal | 147 | 5.7 | 4.9 | 571 |
| diarrhoeaSignal | 615 | 4.1 | 3.9 | 1,511 |
| inappropriate schedule of product administrationSignal | 170 | 4.1 | 3.5 | 400 |
| alopeciaSignal | 176 | 3.9 | 3.4 | 380 |
| astheniaSignal | 217 | 2.5 | 2.2 | 199 |
| deathSignal | 491 | 2.5 | 2.3 | 451 |
| nausea | 281 | 1.5 | 1.4 | 56 |
| fatigue | 273 | 1.5 | 1.4 | 51 |
| vomiting | 145 | 1.3 | 1.1 | 13 |
| off label use | 207 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.